Pharmacology of AMG 416 (velcalcetide), a novel peptide agonist of the calcium-sensing receptor, for the treatment of secondary hyperparathyroidism in hemodialysis patients
作者单位:Amgen, Inc., ASF1-1, 1120 Veterans Blvd., South San Francisco, CA 94080, United States, Department[1]Amgen, Inc., ASF1-1, 1120 Veterans Blvd., South San Francisco, CA 94080, United States[2]